Shasun Pharmaceuticals soars on entering into licensing agreement with Debiopharm Group

10 Apr 2013 Evaluate

Shasun Pharmaceuticals is currently trading at Rs. 68.20, up by 2.80 points or 4.28% from its previous closing of Rs. 65.40 on the BSE.

The scrip opened at Rs. 65.65 and has touched a high and low of Rs. 69.80 and Rs. 65.50 respectively. So far 96386 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 185.90 on 10-Sep-2012 and a 52 week low of Rs. 60.40 on 28-Mar-2013.

Last one week high and low of the scrip stood at Rs. 74.95 and Rs. 64.95 respectively. The current market cap of the company is Rs. 378.98 crore.

The promoters holding in the company stood at 40.95% while Institutions and Non-Institutions held 22.35% and 36.70% respectively.

Shasun Pharmaceuticals, a global pharmaceutical contracting organization offering world class capabilities and facilities to provide services and manufacturing at every scale across the whole drug development lifecycle and Debiopharm Group (Debiopharm) a Swiss-based global biopharmaceutical group with a focus on the development of innovative prescription drugs that target unmet medical needs, entered into a licensing agreement for the manufacturing and commercialization of Huperzine-A.

According to the terms of the agreement, Shasun Pharmaceuticals will be able to use the Debiopharm technology for the manufacture of synthetic Huperzine-A under GMP quality conditions and commercialize it in pharmaceutical and nutraceutical markets. Huperzine-A has shown a significant improvement in memory deficit and cognitive performance in patients with Alzheimer's disease. Huperzine-A is commercially available through Shasun Pharmaceuticals. The synthesis is a result of a joint collaboration between Shasun's research centers in Chennai and the UK.

This technology was recently recognized and awarded at the North East of England Process Industry Cluster (NEPIC), Innovation Awards in 2012. NEPIC is a stand-alone company created to represent the 500+ Pharmaceutical, Biotechnology, Specialty Chemical, Polymer & Rubber, Petrochemical & Commodity Chemical companies based in the North East of England.

Shasun Pharmaceuticals manufactures active pharmaceutical ingredients (APIs), their intermediates and enteric coating excipients with a significant presence in some key generics. Shasun has created a strong product portfolio, building on its R&D Expertise, regulatory capabilities and multi scale production capacities. It is one of the largest producers of Ibuprofen worldwide.

Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×